Navigation Links
RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds,Significant Promise for Treating Breast Cancer

IRVING, Texas--(BUSINESS WIRE)--May 15, 2007 - Reata Pharmaceuticals, Inc. today announced the publication of an article in the May 2007 issue of the journal Cancer Research showing that RTA 402, the company's Phase 2 development candidate for cancer, was highly effective in a rigorous animal model of breast cancer and that the drug inhibits signaling activity of STAT3, an important target for new cancer therapies.

The article, "The Novel Triterpenoid C-28 Methyl Ester of 2-Cyano-3, 12-Dioxooleen-1, 9-Dien-28-Oic Acid Inhibits Metastatic Murine Breast Tumor Growth through Inactivation of STAT3 Signaling," was authored by Reata scientific collaborators from the University of Texas M. D. Anderson Cancer Center.

The authors conducted two studies of RTA 402 in the highly rigorous 4T1 mouse model of breast cancer. Few other agents have shown any effect in this animal model, in which tumors grow very rapidly and become widely distributed, or metastasized, throughout the body. In two separate experiments, treatment with RTA 402 was found to have a profound effect in suppressing the growth and spread of these tumors. In a model mimicking the spread of metastatic disease, RTA 402 completely blocked the development of metastases in all animals, whereas untreated animals developed widespread disease. In a second model mimicking the treatment of established breast tumors, RTA 402 provided a 95% reduction in the total tumor burden of treated animals compared with the untreated control group.

Additionally, the authors showed that this activity was occurring in part through inactivation of STAT3 signaling. STAT3 - short for signal transducer and activator of transcription 3 - is increasingly recognized as an important target for cancer therapies. Activated STAT3 is frequently found in patients with breast cancer and other types of tumors. This protein is known to turn on a number of genes associated with cancer growth, invasion, and metastasis. It has also been shown to have a role in preventing the patient's immune system from recognizing and destroying the tumor. It is thought that cancer therapies able to inhibit STAT3 may have profound anti-cancer effects, which may include re-establishing normal immune function against the tumor. The 4T1 animal studies, which are performed in mice that have a normal immune system, provide support for this idea. When researchers examined the spleens of tumor-bearing animals, they found that untreated control animals had a significant reduction in the number of immune cells in their spleens. Animals receiving RTA 402, however, had levels of immune cells that were consistent with healthy, cancer-free animals.

"This paper provides important new data on how RTA 402 works to inhibit the growth and metastasis of cancer," said Warren Huff, CEO of Reata. "The effects on STAT3 shown in this paper, combined with the drugs' proven inhibition of NF-kB, indicate that these agents modulate important and inter-related pathways in cancer cells."

About Reata

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on selecting and discovering promising early drug development opportunities and translating them into successful marketed drugs that target major unmet clinical needs in cancer, inflammation and neurodegenerative disease. The company's two lead programs are entering advanced clinical trials for deadly, late-stage cancers. In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform that addresses protein misfolding, a key factor in cancer and neurodegenerative disease, to feed its pipeline of small molecule therapeutic candidates. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Founded in 2002, Reata is based in the Dallas area. For more information, visit


For Reata Pharmaceuticals, Inc.
Kathryn Morris, 845-635-9828


Related medicine technology :

1. RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
2. Gabapentin Shown Effective for Fibromyalgia Pain
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
5. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
6. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
7. Accelreon Pharmas ACE-031Shown to Increase Muscle Mass in Preclinical Studies
8. Cethromycin Shown Effective Against Anthrax in Study
9. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
Post Your Comments:
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has ... it. Surviving Mesothelioma has just posted the findings on the website. Click here ... the cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, ... Table 1-1 ). More than 3.7 billion people under the age of 50 – ... according to WHO's first global estimates of HSV-1 infection . , "The data shocks ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by ... of issues that are presently affecting Americans. Dedicated to providing the world with a ... the subjects consumers focus on, one episode at a time. , In the ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to announce ... (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to ... of twelve colleges and universities in the state of California make the cut. CBD ...
Breaking Medicine News(10 mins):